In short
- Researchers re-analysed brain scans of healthy volunteers given LSD, psilocybin, mescaline, MDMA, amphetamine or a placebo.
- The classic psychedelics increased the number of “gateway” regions that gather information into the brain’s global workspace, especially in networks for flexible thinking and attention.
- The more alike two substances’ brain changes were, the more alike people’s experiences were.
What the researchers did
One leading theory of consciousness, the global workspace theory, describes the brain as a theatre: information becomes conscious when it reaches a shared stage and is broadcast widely. Some regions act as gateways that gather information onto the stage, others as broadcasters that send it out. The researchers mapped this workspace in 100 healthy people and then applied the map to brain scans from two placebo-controlled studies in Basel.
What they found
LSD, psilocybin and mescaline all increased the number of gateway regions in the networks that handle flexible control and attention, by about four regions on average, while reducing them in some sensory and emotional areas. MDMA and amphetamine changed the workspace in different ways. Across all the substances, the more similar the brain changes, the more similar the experiences people reported.
Why it matters
People often describe psychedelic states as “more”: more open, more connected, as if everything mattered at once. This study suggests that it is not simply a matter of the whole brain becoming more connected, but of the stage itself being rearranged, with more of the brain’s higher systems gathering what comes in. It is a fascinating picture of how the ordinary boundaries of experience might widen. Brain maps describe; they do not tell us what an experience means. That part stays with the person, and with the work of integration.
Keep in mind
This is a preprint re-analysing resting-state scans from small groups of healthy volunteers, and the gateway measure comes from a computational model. The results need confirming in independent studies.
Experience it for yourself
Our small-group retreats combine careful preparation, ceremonies and integration, led by psychologists and psychotherapists.
See our retreatsThis summary is for information only and is not medical advice. Psychedelics are controlled substances in many countries, including the UK.
You may also like
When the Self Falls Quiet: Ego Dissolution and the Language of the Self
A brain-imaging study found that during strong ego dissolution on psilocybin, people’s language and meaning networks became more alike.
Dr Christoph Zwolan · 12 November 2026
ResearchBelonging, Gratitude and Purpose: Beyond Symptom Relief
In an MDMA-assisted therapy trial for social anxiety, moments of connection and self-transcendent emotion predicted greater belonging, gratitude and purpose.
Danielle Tanner · 10 November 2026
ResearchWhen Nothing Feels Good: Can Psilocybin Help Bring Back Joy?
A small trial tested psilocybin with psychological support for anhedonia, the loss of pleasure, in treatment-resistant depression. The results were mixed but hopeful.
Monika Knitter · 6 November 2026
